FEMY - Femasys Receives 510(k) FDA Clearance to Market FemaSeed

2023-09-26 08:57:55 ET

(24/7 MARKET NEWS) – Femasys Inc. (NASDAQ: FEMY) stated, after yesterday’s market close, that it received 510(k) Clearance from the United States Food and Drug Administration (FDA) for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a woman’s fallopian tube.

Femasys is trading at $0.93, up $0.5984 (+180.66%), on 11.04M premarket shares traded.

Its 52-week range is $0.2479 to $1.7873. If it clears the August resistance points, this could run much higher and challenge the $1.25 inflection point.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is …

The post Femasys Receives 510(k) FDA Clearance to Market FemaSeed appeared first on 24/7 Market News .

For further details see: